Cargando…

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites

BACKGROUND: Real‐world experience with adenoviral vector vaccines against COVID‐19 raised some safety concerns. Cases of cerebral vein thrombosis (CVT) associated with thrombocytopenia have been observed after the first dose of the adenoviral vector vaccines CHADOX1 NCOV‐19 and AD26.COV2.S. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbattista, Maria, Martinelli, Ida, Peyvandi, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420446/ https://www.ncbi.nlm.nih.gov/pubmed/34375510 http://dx.doi.org/10.1111/jth.15493

Ejemplares similares

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018
por: Popiołek, Iwona, et al.
Publicado: (2019)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023)

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
por: Correia Pinheiro, Luis, et al.
Publicado: (2021)

The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions
por: Candore, Gianmario, et al.
Publicado: (2021)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
por: Pop, Gabriela, et al.
Publicado: (2022)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance
por: Pinheiro, Luis C., et al.
Publicado: (2017)

Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
por: Calapai, Fabrizio, et al.
Publicado: (2023)

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection
por: Postigo, Rodrigo, et al.
Publicado: (2018)

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports
por: Baan, Esmé J., et al.
Publicado: (2019)

Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2023)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data
por: Segec, Andrej, et al.
Publicado: (2020)

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives
por: Sardella, Marco, et al.
Publicado: (2019)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
por: Morgovan, Claudiu, et al.
Publicado: (2023)

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
por: Scavone, Cristina, et al.
Publicado: (2022)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
por: Sportiello, Liberata, et al.
Publicado: (2023)

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid‐associated abuse, dependence, or withdrawal
por: Jobski, Kathrin, et al.
Publicado: (2023)

Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance
por: Maltezou, Helena C., et al.
Publicado: (2023)

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
por: Gringeri, Michele, et al.
Publicado: (2021)

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018)

Safety profile of hydroxychloroquine used off‐label for the treatment of patients with COVID‐19: A descriptive study based on EudraVigilance data
por: Motola, Domenico, et al.
Publicado: (2022)

Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study
por: Zinzi, Alessia, et al.
Publicado: (2023)

Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2019)

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)
por: Chiappini, Stefania, et al.
Publicado: (2022)

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated Clostridioides difficile Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
por: Vintila, Bogdan Ioan, et al.
Publicado: (2023)

Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
por: Ehlken, Birgit, et al.
Publicado: (2019)

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis
por: Artoni, Andrea, et al.
Publicado: (2017)

PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
por: di Mauro, Gabriella, et al.
Publicado: (2020)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
por: Maity, Tuhin, et al.
Publicado: (2021)

Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database
por: Jesus, Mafalda, et al.
Publicado: (2023)

Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance
por: Ruggiero, Rosanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lrh4jhbm0712908kp9i9nmlcev